Meeting
2022 ASCO Annual Meeting
BMC128: A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors.
Authors
Corinne Maurice-Dror
BC Cancer, Vancouver, BC, Canada
Corinne Maurice-Dror , Osnat Tirosh , Sheerli Kruger Ben-Shabat , Shiri Eshar , Omri Plolonsky , Noa Davis , Elran Haber , Shiri Meshner , Ruth Perets
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
202122207
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2685)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2685
Abstract #
TPS2685
Poster Bd #
331b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
First Author: Diane Damotte
First Author: Toni K. Choueiri
Poster
2022 ASCO Genitourinary Cancers Symposium
TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.
First Author: Toni K. Choueiri
Poster
2021 ASCO Annual Meeting
Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED).
First Author: Thiago Pimentel Muniz